Want to see KR:008490 full AI Analyst Report?
008490 Stock Chart & Stats
$17850.00
-$40.00(-0.22%)
―
--
Day’s Range― - ―
52-Week Range$16,000.00 - $30,800.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)11.59K
Market Cap
₩198.48B
Enterprise Value$613.61B
Total Cash (Recent Filing)₩71.38B
Total Debt (Recent Filing)₩437.73B
Price to Earnings (P/E)5.1
Beta0.15
Next Earnings
Nov 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.8%
Share Statistics
EPS (TTM)3516.82
Shares Outstanding11,569,113
10 Day Avg. Volume12,600
30 Day Avg. Volume11,590
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.51
Price to Sales (P/S)0.35
P/FCF Ratio6.96
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1,955
Revenue Forecast (FY)₩725.80B
Bulls Say, Bears Say
Bulls Say
Continuing Revenue GrowthRevenue growth continuing through the TTM period and extending expansion since 2023 indicates the company is still broadening its pharmaceutical and healthcare sales base. Although growth has moderated, ongoing top-line expansion can support operating scale and preserve reinvestment capacity over the next several quarters.
Improving LeverageThe decline in debt-to-equity shows balance-sheet repair and a stronger capitalization profile than in 2023. Lower leverage can reduce financial pressure and improve flexibility for funding operations, absorbing business volatility, and supporting investment in the company’s healthcare activities.
Improving Cash GenerationThe sharp improvement in operating cash flow and positive free cash flow demonstrates better internal cash generation than in the weak 2023 period. This gives the company more capacity to fund ongoing operations and investment without relying as heavily on external financing.
Bears Say
Margin CompressionProfitability remains positive, but the decline in net margins from earlier highs indicates that revenue growth is producing less profit than before. Persistent margin pressure could limit earnings expansion, reduce operating resilience, and constrain the cash available for reinvestment.
Lower Return On EquityThe lower return on equity shows that the company is converting its growing equity base into profits less efficiently than it did in 2021. If this persists, capital accumulation may not translate into proportionate earnings growth and could weaken long-term shareholder returns.
Weak Cash ConversionDespite recent cash-flow improvement, the relatively low conversion of net income into free cash flow and modest debt coverage remain structural financial constraints. They reduce the company’s ability to self-fund growth and leave less cash protection against operating or financing demands.
008490 FAQ
What was Suheung Co. Ltd.’s price range in the past 12 months?
Suheung Co. Ltd. lowest stock price was $16000.00 and its highest was $30800.00 in the past 12 months.
What is Suheung Co. Ltd.’s market cap?
Suheung Co. Ltd.’s market cap is ₩198.48B.
When is Suheung Co. Ltd.’s upcoming earnings report date?
Suheung Co. Ltd.’s upcoming earnings report date is Nov 18, 2026 which is in 19 days.
How were Suheung Co. Ltd.’s earnings last quarter?
Suheung Co. Ltd. released its earnings results on Aug 13, 2026. The company reported $1231.205 earnings per share for the quarter.
Is Suheung Co. Ltd. overvalued?
According to Wall Street analysts Suheung Co. Ltd.’s price is currently Undervalued.
Does Suheung Co. Ltd. pay dividends?
Suheung Co. Ltd. pays a Annually dividend of $500 which represents an annual dividend yield of 2.8%. See more information on Suheung Co. Ltd. dividends here
What is Suheung Co. Ltd.’s EPS estimate?
Suheung Co. Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Suheung Co. Ltd. have?
Suheung Co. Ltd. has 11,569,113 shares outstanding.
What happened to Suheung Co. Ltd.’s price movement after its last earnings report?
Suheung Co. Ltd. reported an EPS of $1231.205 in its last earnings report. Following the earnings report the stock price went down -0.183%.
Which hedge fund is a major shareholder of Suheung Co. Ltd.?
Currently, no hedge funds are holding shares in KR:008490
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Suheung Co. Ltd.
Suheung Co., Ltd. specializes in the production and provision of empty hard capsules, which are primarily utilized within the pharmaceutical and nutraceutical industries. The company further diversifies its business by offering comprehensive contract manufacturing services, accommodating a wide array of dosage types and packaging arrangements. Additionally, Suheung provides original equipment manufacturing (OEM) for paintball products. This South Korean firm, headquartered in Seoul, began its operations in 1973.
Technical Analysis
YUNGJIN PHARM. CO. LTD
―
Hyundai Pharmaceutical Co., Ltd.
―
Samjin Pharmaceutical Co., Ltd.
―
Kwang Dong Pharmaceutical Co., Ltd.
―
KOREA UNITED PHARM, INC.
―